pharmacy and therapeutics committee improvements. Sec. 202. Improving reporting requirements and developing standards for the use of drug use review boards in State Medicaid programs. Sec. 203. GAO report on conflicts of interest in State Medicaid program drug use review boards and pharmacy and therapeutics (P&T) committees. Sec. 204. Ensuring the accuracy of manufacturer price and drug product information under the Medicaid drug rebate program. Sec. 205. Excluding authorized generic drugs from calculation of average manufacturer price under the Medicaid drug rebate program. Sec. 206. Improving transparency and preventing the use of abusive spread pricing and related practices in Medicaid. Sec. 207. T–MSIS drug data analytics reports. Sec. 208. Risk-sharing value-based payment agreements for covered outpatient drugs under Medicaid. Sec. 209. Modification of maximum rebate amount under Medicaid drug rebate program. Sec. 210. Applying Medicaid drug rebate requirement to drugs provided as part of outpatient hospital services. I Medicare A Part B 101. Improving manufacturers' reporting of average sales prices to set accurate payment rates (a) In general Section 1847A(f) of the Social Security Act (42 U.S.C. 1395w–3a(f)) is amended— (1) by striking price .—For requirements and inserting “ price .— (1) In general For requirements